Hood National Law Group https://www.nationalinjuryhelp.com Representing Injured People Worldwide Wed, 24 May 2017 20:51:22 +0000 en-US hourly 1 Invokana gets Black Box Warning from FDA https://www.nationalinjuryhelp.com/dangerous-drugs/invokana-black-box-warning-fda/ https://www.nationalinjuryhelp.com/dangerous-drugs/invokana-black-box-warning-fda/#respond Tue, 16 May 2017 16:06:32 +0000 https://www.nationalinjuryhelp.com/?p=36418 May 16, 2017 – San Diego, CA.  Last year at almost the exact day, the FDA issues a warning for people taking a diabetes drug called Invokana.  Here is the original blog post disusing the FDA warning from last year:

“FDA is alerting the public about interim safety results from an ongoing clinical trial that found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with the diabetes medicine canagliflozin (Invokana, Invokamet). FDA has not determined whether canagliflozin increases the risk of leg and foot amputations. FDA is currently investigating this new safety issue and will update the public when we have more information.”

Now as of today, the FDA is now taking the warning to the most extreme level, the Boxed Warning. Invokana FDA Box Warning

The FDA Black Box warning is the highest level of warning issued to drugs. Many times if a drug continues to have adverse affects, it may then be recalled by the manufacturer or issued by the FDA.

The new data was complied by two very large and new clinical trials, the CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus).

In these two studies the researchers warn of the increased risk of leg and foot amputations. FDA is requiring new warnings, including the most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.

Not the only FDA warning for Invokana.

On top of warnings from the FDA, there are more concerns when it comes to this drug. The Institute for Safe Medication Practices (ISMP) published a warning in their May 6th edition of Quarter Watch which warns about a number of adverse reactions being reported to the FDA about Invokana.

In the first year after Invokana was released, there were over 450 adverse event reports filed.

  • 54 reports of kidney failure
  • 54 cases of severe hydration or fluid imbalance
  • 11 cases of kidney stones
  • 50 cases or urinary tract infections
  • 52 cases of abnormal weight loss
  • 50 cases of hypersensitivity (swelling of the tongue, lips, throat, face)

Links and sources:

Learn about the Invokana lawsuits going on.

FAQs on Invokana here.

https://www.fda.gov/Drugs/DrugSafety/ucm557507.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

]]>
https://www.nationalinjuryhelp.com/dangerous-drugs/invokana-black-box-warning-fda/feed/ 0
Dangers and Side Effect Risks for 1 in 3 FDA Approved Drugs https://www.nationalinjuryhelp.com/dangerous-drugs/dangers-side-effect-risks-1-3-fda-approved-drugs/ https://www.nationalinjuryhelp.com/dangerous-drugs/dangers-side-effect-risks-1-3-fda-approved-drugs/#respond Thu, 11 May 2017 18:21:59 +0000 https://www.nationalinjuryhelp.com/?p=36399 May 11, 2017 – San Diego, CA — A new American Medical Association study released on May 9, 2017 illustrates that, in our opinion, the FDA is either broken or fails to study new drugs adequately before being sent to the market.

The study looked at new drugs approved by the FDA from the years 2001 through 2010.

The study found that 32% of these new drugs had some type of post-market safety event (side effect).  Three drugs were pulled from the market in recalls, and 61 were assigned FDA Black Box warnings, which is the most severe warning from the FDA.  Many times after a black box warning is issued, the next step is a recall.

71 drugs approved by the FDA were later found to have 123 safety events. This is simply absurd. Why must the American people be the testing ground for these new drugs?

The FDA is trying to fast track these new drugs to the market.  Is it pressure from Bug Pharma looking to increase its ever growing revenue? Or is the FDA so bloated as a bureaucracy that it simply can’t keep up?

Regardless of the politics on the issue, the bottom line is that we the people are now being the guinea pigs for drug companies. Our safety is at risk.  The public should demand that all drugs being reviewed should have longer testing periods and or a larger study group to insure that these new drugs are indeed safe for the public at large.  

It usually takes a drug company 5 years to get a new drug to the market.  Drug companies perform their own clinical trials then submit to the FDA.  This may seem like a long period of time, but when the study points out the 32% of new drugs have problems, maybe this is too short of a development process. Now our new administration lead by President Trump wants to make this process even faster!

What is the FDA GRAS list? (Generally Recognized as Safe)

Just reading the Generally Recognized as Safe makes me wonder what this actually means. So let’s get the answer from the FDA website:

“GRAS” is an acronym for the phrase Generally Recognized As Safe. Under sections 201(s) and 409 of the Federal Food, Drug, and Cosmetic Act (the Act), any substance that is intentionally added to food is a food additive, that is subject to premarket review and approval by FDA, unless the substance is generally recognized, among qualified experts, as having been adequately shown to be safe under the conditions of its intended use, or unless the use of the substance is otherwise excepted from the definition of a food additive.

In my mind this entire GRAS system is simply a well let’s just wait and see if something happens to people.  Again this illustrates that the FDA isn’t truly serving the American people.  Given that people tend to trust the medication that they take, most are not completely aware of the risks that they may be facing.

Marketing to Doctors versus Research and Development.

Another problem that most people don’t know is the fact that Big Pharma spends more money marketing to doctors, than on research and development.  What’s wrong with the picture?

Examples of Drug Marketing Cost versus Research and Development include:

  • Johnson & Johnson spent $17. 5 billion on marketing in 2013 versus $8.2 billion in R&D
  • Pfizer spent $11.4 billion versus $6.6 billion in R&D.
  • GlaxoSmithKline spent $9.9 billion versus $5.3 billion in R&D.

Most of these marketing dollars are directed at doctors, and not the general public.

As noted on Last Week Tonight with John Oliver on this topic, Oliver puts it this way:

“Ask your doctor today if he’s taking pharmaceutical company money. Then ask your doctor what the money is for, ask your doctor if he’s taken any money from the companies who make the drugs he just prescribed for you. Then ask yourself if you’re satisfied with that answer.”

Another study released a few days ago mentioned that when teaching hospitals don’t allow pharmaceutical sales reps in the building, the doctors don’t prescribe those drugs.  Are we seeing a pattern here?

Every drug recalled by the FDA was once approved by the FDA.

Drug recalls can be by a company’s own initiative, by an FDA request, or by the FDA under statutory authority.  Recalls by the FDA are classified as either:  Class I, Class II and Class III.FDA recalled drugs

Class I recalls means there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death. 

 

There have been numerous drugs over the years that have not only had severe side effects, but many that have in fact led to a person’s death.  A quick view of Wikipedia shows a large list of drug recalls dating all the way back to 1960.

Examples of recent large drug recalls includes:

  • 2010 Darvon/Darovcet – risk of heart attacks and stroke.
  • 2010 Mylotarg – risk of death.
  • 2010 Avandia recalled in Europe – risk of heart attack and death, still sold in US!
  • 2010 Meridia – risk of heart attack and stroke.
  • 2008 Trasylol – risk of death.
  • 2007 Zelnorm – risk for heart attack, stroke, and unstable angina.
  • 2004 Vioxx – risk of myocardial infarction and stroke.
  • 2004 Bextra – risk of heart attack and stroke.

Who stands up for the People’s Rights? Who fights Big Pharma?

It’s well known that Big Pharma is collectively a massive and powerful group of companies with combined earnings in the billions. They are the number one lobbying group in Washington DC and they continue to pressure or government to ease back regulations pertaining to them.

Consumers who are harmed by the use of defective medications and who attempt to stand up for themselves soon realize that they are up against a corporate behemoth with billions of dollars at their disposal.  These resources are often put to use by way of retaining extremely skilled defense attorneys and other professionals whose job is to protect the legal and financial interests of their clients.  Simply put, an individual consumer working without legal help against a worldwide corporation is not a fair fight.

Lawyer Richard Hood at National Injury Help

Lawyer Richard Hood

The defective drugs lawyers at the Hood National Law Group have been leveling the playing field for consumer clients in these matters across the United States for decades.  We have taken on several enormous corporations and earned positive results because we understand how to hold wrongdoers accountable.

If you or someone you love has suffered as a result of trusting any of these medications, contact the defective drugs lawyers at the Hood National Law Group, today to schedule a free initial consultation.

Sources:

http://jamanetwork.com/journals/jama/article-abstract/2625319

https://www.fda.gov/drugs/drugsafety/drugRecalls/default.htm

https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research/?utm_term=.6f85b9627327

https://en.wikipedia.org/wiki/List_of_withdrawn_drugs

]]>
https://www.nationalinjuryhelp.com/dangerous-drugs/dangers-side-effect-risks-1-3-fda-approved-drugs/feed/ 0
Woman to protest against Bayer’s Essure birth control device. https://www.nationalinjuryhelp.com/defective-products/woman-protest-essure-device/ https://www.nationalinjuryhelp.com/defective-products/woman-protest-essure-device/#respond Mon, 01 May 2017 16:29:49 +0000 https://www.nationalinjuryhelp.com/?p=36349 May 1, 2017 San Diego, CA —  Woman from around the US are getting ready for a protest this coming Saturday against Bayer Pharmaceuticals birth control device called Essure.

Essure has been making headlines ever since thousands of women began speaking out against the permanent form of birth control and the serious side effects it can potentially cause.

There has been 9,900 “adverse event reports” sent to the FDA between 2002 and 2015, yet as of today the FDA is still allowing Essure to be sold in the US, even though other counties has banned its use. Between 2002 and 2015, over 630 pregnancies were reported to the FDA by women who had Essure inserted but became pregnant anyway.

The group of victims started as a Facebook community called E-Sisters which provides support and outreach for any women hurt or suffering from the Essure birth control device.

Essure is a form of permanent birth control (sterilization) that involves placing two metal coils in a woman’s fallopian tubes. Essure is the only non-surgical form of permanent contraception available today. The procedure is performed in a doctor’s office usually in less than 30 minutes.Essure coils broken

Essure has been linked to a multitude of adverse side effects by thousands of women who had the metal coils inserted. Side effects can range from mild to severe; some may even be life-threatening.  The only way to remove Essure is to have a complete hysterectomy.

Plans call on staging protests in various cities across the nation.  May 6th, 2017 is the day when these victims raise their voices in hopes of pressuring both the FDA and Bayer into recalling this terrible device, which has caused so many woman pain and suffering.

List of Cities for the May 6 Essure Rally include:

Arizona – Mesa

Arkansas – Little Rock

California – Berkley, San Diego

Colorado – Denver

Florida – Jacksonville

Idaho – Meridian

Indiana – Portage

Missouri – Kansas City

Montana – Missoula

North Carolina – Raleigh

Nevada – Las Vegas

New Jersey – Whippany

Ohio – Dayton

Texas – Austin, Dallas, Houston, San Antonio, Midland Odessa

Virginia – Norfolk

We support and stand by all women who have been harmed from this terrible device and hope that you share this event on you social media channels.

If you or someone you love has been hurt from Essure, please contact us today as we intent to hold Bayer Pharmaceuticals responsible for the suffering it’s caused.

]]>
https://www.nationalinjuryhelp.com/defective-products/woman-protest-essure-device/feed/ 0
Xarelto Lawsuit Update News https://www.nationalinjuryhelp.com/dangerous-drugs/xarelto-lawsuit-update-news/ https://www.nationalinjuryhelp.com/dangerous-drugs/xarelto-lawsuit-update-news/#respond Fri, 24 Mar 2017 16:57:01 +0000 https://www.nationalinjuryhelp.com/?p=36043 March 24, 2017 – The number of Xarelto lawsuits are approaching nearly 17,000 lawsuits against the makers of Xarelto, Johnson & Johnson subsidiary Janssen Pharmaceuticals, pending across the country.

Plaintiffs and defendants meet March 23 for oral arguments regarding the first and second bellwethers.

Xarelto Lawsuits accuse Janssen of designing a defective product and hiding the risks associated with it from the public. There could be a fund set aside for bleeding victims that could have high value cash payouts from a pending class action lawsuit. Xarelto Lawsuit Update News

The first bellwether trial in the Xarelto multidistrict litigation (MDL) set to begin in April 2017. This high visibility lawsuit was delayed in February.

The following Xarelto lawsuit cases were chosen as bellwethers:

Boudreaux, Jr. et al v. Janssen Research & Development LLC et al  (2:14-cv-02720)

Orr et al v. Janssen Research & Development LLC et al (2:15-cv-03708)

Mingo v. Janssen Research & Development LLC et al (2:15-cv-03469)

Henry v. Jansen Research & Development LLC et al (2:15-cv-00224)

New studies do show Xarelto is an effective medication for the treatment of blood clots, but other studies indicate possible uncontrollable bleeding events.

Reports of side effects:

The most common side effect of Xarelto is the risk of bleeding. Xarelto increases the risk of bleeding and can cause serious or fatal bleeding, the drug’s label states. People taking Xarelto should watch for the following signs and symptoms of bleeding:

  • Unexpected bleeding or bleeding that lasts a long time, such as
    • Nose bleeds that happen often
    • Unusual bleeding from the gums
    • Menstrual bleeding that is heavier than normal or vaginal bleeding
    • Bleeding that is severe or you cannot control
    • Red, pink or brown urine
    • Bright red or black stools
    • Cough up blood or blood clots
    • Vomit blood or your vomit looks like coffee grounds
    • Headaches, feeling weak or dizzy
    • Pain, swelling or new drainage at wound sites

I was harmed after taking Xarelto. How do I file a claim?
If you or a loved one took Xarelto and suffered a major bleeding episode, you may be entitled to compensation. The first step in filing a Xarelto Claim is to call the Hood National Law Group today at 1-800-214-1010 for a free case evaluation or use the secure intake form on the right-hand side of your screen.

Xarelto Lawsuits in these States – Click on your State:

Alabama (AL), Alaska (AK), Arizona (AZ), Arkansas (AR), California (CA), Colorado (CO), Connecticut (CT), Delaware (DE), Georgia (GA), Hawaii (HI), Idaho (ID), Illinois (IL), Indiana (IN), Iowa (IA), Kansas (KS), Kentucky (KY), Louisiana (LA), Maine (ME), Maryland (MD), Massachusetts (MA), Minnesota (MN), Mississippi (MS), Missouri (MO), Montana (MT), Nebraska (NE), Nevada (NV), New Hampshire (NH), New Jersey (NJ), New Mexico (NM), New York (NY), North Carolina (NC), North Dakota (ND), Ohio(OH), Oklahoma (OK), Oregon (OR), Pennsylvania (PA), Rhode Island (RI), South Carolina (SC), South Dakota (SD), Tennessee (TN), Texas (TX), Utah (UT), Vermont (VT), Virginia (VI), Washington (WA), West Virginia (WV), Wisconsin (WI), Wyoming (WY)
Xarelto Lawsuit Update News published on March 28, 2017.

]]>
https://www.nationalinjuryhelp.com/dangerous-drugs/xarelto-lawsuit-update-news/feed/ 0
France opens investigation into chemotherapy drug Taxotere following the deaths of 5 women https://www.nationalinjuryhelp.com/dangerous-drugs/france-investigates-taxotere-deaths/ https://www.nationalinjuryhelp.com/dangerous-drugs/france-investigates-taxotere-deaths/#respond Fri, 10 Mar 2017 20:17:22 +0000 https://www.nationalinjuryhelp.com/?p=35965 Taxotere lawsuitsMarch 10, 2017 – San Diego, CA — French regulators are investigating the deaths of 5 women who took the chemotherapy drug docetaxel to treat breast cancer.

Docetaxel is the generic name of brand name Taxotere.

France’s National Agency for the Safety of Medicines and Health Products (ANSM) issued information about the deaths on its website and sent letters to the country’s oncologists last month.

In the letter, the agency said it had received information about six incidents of neutropenic enterocolitis in women treated with docetaxel for breast cancer. The women were all between the ages of 46 and 73 and five died as a result of their condition.

The incidents reportedly occurred between August 2016 and February 2017.

One day after ANSM sent its letter to oncologists, it issued another letter recommending docetaxel not be used to treat “localized, operable breast cancer.” The agency said paclitaxel is an alternative medicine on the market and should be used instead.

Docetaxel is indicated to treat other cancers other than breast cancer and the agency did not recommend doctors stop using docetaxel for those other indications.

ANSM said in its letter that the batches of docetaxel were immediately checked and found to be in compliance.

Neutropenic enterocolitis is a condition that affects the cecum, a pouch that connects the small and large intestines. The condition has typically been seen in children undergoing chemotherapy for leukemia, according to Medscape.

An abnormally low count of one type of white blood cell, a condition called neutropenia, appears to be the common denominator in the onset of neutropenic enterocolitis, Medscape indicates.

According to ANSM, neutropenia is the most common adverse reaction associated with docetaxel and Tatorere reported to the agency.

Taxotere and permanent hair loss

Taxotere has been associated with another, non-life-threatening condition known as permanent alopecia, or permanent hair loss. Some women who took Taxotere to treat breast cancer have reported suffering from permanent alopecia and have begun filing Taxotere Lawsuits against the maker of Taxotere, Sanofi, in the United States.

If you underwent chemotherapy treatment with Taxotere and suffered permanent hair loss as a result, you may be entitled to compensation.

The experienced Taxotere attorneys at Hood National Law Group are ready to hear your story and help you file a claim if you qualify.

Call Hood National Law Group today at 1-800-214-1010 for a free case evaluation or use the form on the right-hand side of the screen.

]]>
https://www.nationalinjuryhelp.com/dangerous-drugs/france-investigates-taxotere-deaths/feed/ 0
New trial schedule sees first Xarelto bellwether starting in April https://www.nationalinjuryhelp.com/dangerous-drugs/first-xarelto-bellwether-trial-april/ https://www.nationalinjuryhelp.com/dangerous-drugs/first-xarelto-bellwether-trial-april/#respond Fri, 10 Mar 2017 00:36:37 +0000 https://www.nationalinjuryhelp.com/?p=35961 Xarelto lawsuitsMarch 9, 2017 – San Diego, CA — Plaintiffs and defendants are gearing up for the first bellwether trial in the Xarelto multidistrict litigation (MDL) set to begin next month.

The trial is slated for April 24 in the Eastern District of Louisiana, where less than two dozen Xarelto lawsuits were first consolidated in December 2014.

Today, there are more than 15,000 lawsuits filed in the MDL and nearly 17,000 are filed in total nationwide.

Xarelto lawsuits involve allegations that the blood-thinning drug can cause uncontrollable and life-threatening bleeding episodes in some people.

Next month’s trial comes after a series of delays pushed back its scheduled start date. There are four Xarelto bellwether trials altogether and they were originally expected to begin in early February.

First, the trials were set back because the NBA All-Star Games were relocated from North Carolina to New Orleans in response to the state’s controversial “bathroom bill.”

Then the trials were pushed back a second time at the request of both parties last month, delaying the trials until April.

Plaintiffs and defendants are due to meet March 23 for oral arguments regarding the first and second bellwethers.

Bellwether Trial Schedule

District Judge Eldon E. Fallon issued a case management order on Jan. 30, laying out the new bellwether trial schedule as follows:

  • First trial — April 24, 2017 in the Eastern District of Louisiana
  • Second trial — May 30, 2017 in the Eastern District of Louisiana
  • Third trial — To Be Set in June 2017 in the Southern District of Mississippi
  • Fourth trial — To Be Set in July 2017 in the Northern District of Texas

The following cases were chosen as bellwethers:

  1. Boudreaux, Jr. et al v. Janssen Research & Development LLC et al  (2:14-cv-02720)
  2. Orr et al v. Janssen Research & Development LLC et al (2:15-cv-03708)
  3. Mingo v. Janssen Research & Development LLC et al (2:15-cv-03469)
  4. Henry v. Jansen Research & Development LLC et al (2:15-cv-00224)

First Bellwether Case

The Xarelto lawsuit chosen as the first bellwether was filed Dec. 1, 2014, less than two weeks before the Xarelto MDL was formed.

Louisiana resident Joseph Boudreaux Jr. filed the case accusing Xarelto’s manufacturers of designing a defective product and concealing the risks of the drug from the healthcare community, the U.S. Food and Drug Administration, and the public in general, according to the lawsuit.

Boudreaux first began taking Xarelto in January 2014. He was prescribed the drug to treat his atrial fibrillation, a condition in which the heart beats irregularly and causes poor blood flow.

The plaintiff had only been taking Xarelto for about a month when he suffered a severe gastrointestinal bleed and had to be hospitalized, according to court documents.

Boudreaux received several blood transfusions as a result of the internal bleeding and spent four nights in two different hospitals.

He is suing the makers of Xarelto — Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, along with healthcare giant Bayer – on 12 counts, including product liability, negligence, and fraud.

Xarelto Lawsuits

There are more than 15,000 Xarelto lawsuits pending in the multidistrict litigation in the Eastern District of Louisiana and nearly 17,000 lawsuits are pending nationwide.

If you were injured by Xarelto, there is still time to file a Xarelto Lawsuit, but you need to act fast! Xarelto bellwether trials are scheduled to start in April 2017 and they could take the parties one step closer towards a global settlement.

The experienced legal team at Hood National Law Group is ready to answer your questions and help you file a claim for compensation. Call us today at 1-800-214-1010 for a free case evaluation.

]]>
https://www.nationalinjuryhelp.com/dangerous-drugs/first-xarelto-bellwether-trial-april/feed/ 0
Xarelto sales increase along with lawsuits https://www.nationalinjuryhelp.com/dangerous-drugs/xarelto-sales-lawsuits/ https://www.nationalinjuryhelp.com/dangerous-drugs/xarelto-sales-lawsuits/#respond Thu, 09 Mar 2017 01:11:33 +0000 https://www.nationalinjuryhelp.com/?p=35954 xarelto lawsuitsMarch 8, 2017 – San Diego, CA — 2016 was a big year for Johnson & Johnson’s oral anticoagulant Xarelto.

The blockbuster drug brought in more than $2.2 billion in sales for the company and its Janssen Pharmaceuticals division. That’s an increase of about $420 million – or 22.5% — from 2015, according to J&J’s annual report released Feb. 27.

Strong sales aren’t the only big numbers facing J&J and its anticoagulant. There are roughly 16,900 Xarelto lawsuits now pending in state and federal courts nationwide, according to the same annual report. And more are expected to be filed.

These lawsuits accuse J&J and Janssen of designing a defective drug and failing to adequately warn about its risks. Xarelto has been associated with an increased risk of uncontrollable bleeding, especially gastrointestinal, rectal, and brain bleeds.

Although all anticoagulants increase the risk for bleeding, Xarelto is especially dangerous because there is no approved antidote to stop a Xarelto bleed. People have suffered life-threatening bleeds that left them hospitalized and some have reportedly died as a result of taking the drug.

FDA approves Xarelto without antidote to stop bleeding

Xarelto was approved by the U.S. Food and Drug Administration nearly six years ago in July 2011, despite the fact that there was approved antidote to stop a bleed.

The drug was originally approved to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in people undergoing hip or knee replacement surgery. DVT occurs when a blood clot forms in one of the body’s deep veins, usually in the leg. PE occurs when that blood clot breaks off and travels to the lungs.

About a year and a half after its initial approval, Xarelto’s use was expanded to include the prevention of DVT and PE and to reduce the risk of stroke in patients with the heart condition atrial fibrillation.

Numerous studies have linked the anticoagulant to an increased risk for bleeding, including a study published in BMJ a year after Xarelto’s approval concluding it was “generally associated with a higher bleeding tendency.”

Xarelto LawsuitsWithout an approved antidote, a Xarelto bleed can be life-threatening.

A Xarelto antidote is being developed by the pharmaceutical company Portola, but its approval was stalled by the FDA in August last year. The regulatory agency said it needed more information about the breakthrough therapy before it could approve it.

Even with an approved antidote, Xarelto patients are still at an increased risk for side effects.

Xarelto side effects include:

  • Gastrointestinal (GI) and other internal bleeding
  • Brain hemorrhaging
  • Stroke
  • Death from bleeding out
  • Heart attack
  • Pulmonary embolism
  • Organ failure

Xarelto Bleeding Lawsuits

There are nearly 17,000 lawsuits against the makers of Xarelto, Johnson & Johnson subsidiary Janssen Pharmaceuticals, pending across the country.

Xarelto Lawsuits accuse Janssen of designing a defective product and hiding the risks associated with it from the public.

If you or a loved one took Xarelto and suffered a major bleeding episode, you may be entitled to compensation. Call the Hood National Law Group today at 1-800-214-1010 for a free case evaluation or use the form on the right-hand side of your screen.

]]>
https://www.nationalinjuryhelp.com/dangerous-drugs/xarelto-sales-lawsuits/feed/ 0
Risperdal gynecomastia lawsuit tossed by judge a week before trial https://www.nationalinjuryhelp.com/dangerous-drugs/risperdal-gynecomastia-lawsuit-tossed/ https://www.nationalinjuryhelp.com/dangerous-drugs/risperdal-gynecomastia-lawsuit-tossed/#respond Wed, 08 Mar 2017 01:03:36 +0000 https://www.nationalinjuryhelp.com/?p=35945 Risperdal gynecomastia lawsuitMarch 7, 2017 – San Diego, CA — A Risperdal gynecomastia lawsuit slated for trial Monday was tossed by the presiding judge last week.

It would have been the seventh case to go before a jury in the Risperdal mass tort program in Philadelphia’s Court of Common Pleas.

As reported by Law360, Judge Arnold New issued a one-page order on Feb. 28 granting summary judgment in favor of Janssen Pharmaceuticals Inc., a division of Johnson & Johnson and the maker of Risperdal.

Judge New granted summary judgment on each count of the plaintiff’s lawsuit, which accused Janssen of failing to adequately warn about the risks related to Risperdal, among other claims.

Risperdal is an antipsychotic medication used to treat certain mental illnesses in adults and kids. The drug has been linked to a condition known as gynecomastia, which causes male breast tissue to swell to an unusually large size.

The unidentified plaintiff in the case reportedly began taking Risperdal when he was just 8 years old to treat symptoms of attention deficit hyperactivity disorder (ADHD).

Attorneys representing the plaintiff reportedly told Law360 that the judge’s decision was based on Janssen’s argument that testimony from the plaintiff’s prescribing physician did not satisfy the learned intermediary doctrine, which requires proof that a different warning would have changed the treatment plan.

The plaintiff’s prescribing physician reportedly testified that he would have tossed Risperdal as a potential treatment if he had been given accurate warnings.

But another treating physician testified she would have continued to prescribe Risperdal even if she received a different warning because the benefits outweighed the risks, according to Law360.

Plaintiff’s attorneys told the publication they planned to appeal the ruling.

A spokesperson for Janssen told Law360 the company believed the judge had “acted appropriately in granting our motion for summary judgment based on the facts of the case.”

Another Risperdal gynecomastia case is slated for trial on March 20, according to court records.

Janssen has filed a motion for summary judgment in that case, as well, but Judge New has not yet answered the motion.

The case is P.D. et al v. Janssen Pharmaceuticals et al (130600738) in the Philadelphia Court of Common Pleas.

Risperdal Gynecomastia Lawsuits

There are more than 5,000 Risperdal lawsuits pending in the mass tort in Philadelphia’s Court of Common Pleas and more than 18,500 are pending nationwide.

Risperdal Gynecomastia Lawsuits accuse the maker of Risperdal, Janssen Pharmaceuticals, of designing a defective product and failing to warn about its risks, including its potential to cause gynecomastia.

If you or someone you love took Risperdal and developed gynecomastia, you may be entitled to financial compensation.

The attorneys at Hood National Law Group fight every day for the rights of consumers and can help you get the justice you deserve. Call Hood National today to speak with a member of our legal team and see if your case qualifies for a Risperdal Lawsuit. Call 1-800-214-1010 or use the form on the right-hand side of your screen. The consultation is free and there is no obligation.

]]>
https://www.nationalinjuryhelp.com/dangerous-drugs/risperdal-gynecomastia-lawsuit-tossed/feed/ 0
3 things you need to know about Xarelto and alcohol use https://www.nationalinjuryhelp.com/dangerous-drugs/xarelto-and-alcohol-use/ https://www.nationalinjuryhelp.com/dangerous-drugs/xarelto-and-alcohol-use/#respond Tue, 07 Mar 2017 00:34:09 +0000 https://www.nationalinjuryhelp.com/?p=35880 Xarelto and alcohol useXarelto hit the market in 2011 and has since become one of the best-selling blood thinners on the market. Last year, the drug brought in more than $2.2 billion for its manufacturers.

For millions of people using Xarelto, this important question often comes up: Is it safe to drink alcohol while taking Xarelto?

Before you reach for that drink, here are a few things you need to know about Xarelto and alcohol use.

1. Xarelto thins your blood. So does alcohol.

There’s a reason Xarelto is called a “blood thinner.” The medication works to stop your blood from clotting in order to reduce your chance of a heart attack, stroke, or other clot-related injuries.

Because Xarelto stops blood from clotting, people who take the medication are at risk of severe, uncontrollable bleeding. This is true of all anticoagulants, including the traditional blood thinner warfarin (Coumadin).

What makes a Xarelto-bleeding episode especially dangerous is the fact that no approved antidote exists to stop the bleeding. This can turn a relatively benign cut into a potentially deadly condition.

Alcohol acts as a blood thinner too, which makes the combination Xarelto + Alcohol even more dangerous.

The physicians at WebMD recommend drinking no more than two drinks per day while taking Xarelto, or any other blood thinner. They also suggest talking with your doctor about Xarelto and alcohol use.

Xarelto and alcohol use2. Your liver breaks down Xarelto and alcohol, but not at the same time

Not only do Xarelto and alcohol both act as blood thinners, they are also both broken down (processed) by the liver.

When you drink, your liver might turn its attention to breaking down alcohol instead of processing your blood thinning medication. WebMD cautions that this can lead to excess amounts of Xarelto in your bloodstream, which raises your risk for bleeding.

3. Regular drinkers might need to get their blood monitored

Xarelto is a new kind of anticoagulant that does not require routine blood monitoring, unlike its predecessor warfarin. This is what made Xarelto and other novel oral anticoagulants (NOACs) so appealing to millions of people.

But the convenience of not having to get your blood levels checked means you don’t know exactly how much of the medication is in your body. For regular drinkers, this could spell trouble.

Xarelto increases a person’s risk for bleeding. Adding alcohol into the mix increases those risks even more. If you’re a regular drinker, you may need to monitor your blood levels when taking Xarelto, or drink less alcohol.

Xarelto and alcohol use

The bottom line is…

Xarelto increases your risk of uncontrollable bleeding and alcohol only increases this risk.

It may be safe to knock a couple drinks back while taking Xarelto, but you should probably speak with your doctor about your risk of bleeding beforehand.

Remember, every body is different.

Xarelto Bleeding Lawsuits

Xarelto’s potential to cause serious, uncontrollable bleeding has prompted thousands of people injured by the drug to file lawsuits against its manufacturers, Bayer and Johnson & Johnson’s subsidiary Janssen Pharmaceuticals.

Xarelto lawsuitThere are more than 15,000 Xarelto lawsuits pending in a multidistrict litigation in Louisiana’s Eastern District.

Xarelto Lawsuits accuse Bayer and Janssen of designing a defective product and hiding the risks associated with it from the public.

If you or a loved one took Xarelto and suffered a major bleeding episode, you may be entitled to compensation. Call the Hood National Law Group today at 1-800-214-1010 for a free case evaluation or use the form on the right-hand side of your screen.

Photo credit:
First photo: Credit: Shutterstock.com/Dmytro Zinkevych
Third photo: Credit: Shutterstock.com/Iakov Filimonov

]]>
https://www.nationalinjuryhelp.com/dangerous-drugs/xarelto-and-alcohol-use/feed/ 0
Product in Place lawsuits an option for IVC filter patients with no complications https://www.nationalinjuryhelp.com/defective-products/ivc-filter-lawsuits-without-complications/ https://www.nationalinjuryhelp.com/defective-products/ivc-filter-lawsuits-without-complications/#respond Sat, 04 Mar 2017 00:36:16 +0000 https://www.nationalinjuryhelp.com/?p=35866 ivc filter lawsuit

Do you have a retrievable IVC filter implanted but haven’t suffered any known complications? You may still be able to file a claim.

March 3, 2017 – San Diego, CA — People who have retrievable IVC filters implanted but haven’t noticed any symptoms of complications may still be eligible for an IVC filter claim. These claims are called Product in Place, or PIP.

IVC filters are small, cage-like devices designed to trap blood clots before they travel to the heart or lungs. A blood clot that reaches the heart can cause a heart attack; a blood clot that reaches the lungs causes pulmonary embolism, a life-threatening condition.

IVC filters are surgically implanted in a person’s inferior vena cava (IVC), the large vein in the abdomen that carries blood from the lower half of the body to the heart. They are often implanted in people who cannot use traditional blood thinners or who have suffered trauma and are at immediate risk for blood clots.

When these filters were first introduced several decades ago, they were designed to remain in the body indefinitely. Then, in the early 2000s, medical device manufacturers began developing “retrievable” IVC filters.

These new filters were supposed to be removed once a person’s risk for blood clots had subsided. The U.S. Food and Drug Administration reiterated the importance of this in two communications to physicians — one sent in 2010 and the other in 2014.

The agency reminded physicians to remove IVC filters as soon as a patient’s risk for blood clots had subsided. In general, the FDA recommended IVC filters be removed between 29 and 54 days after implantation.

Bard IVC FilterWhy? Because leaving retrievable IVC filters in too long increases a person’s risk for serious complications related to the devices.

IVC filters have been known to migrate from the inferior vena cava to other parts of the body, including the heart and lungs. The filters can tilt within the vein, fracture or break, and embed themselves within the vein or nearby organs.

These complications put patients at increased risk for other serious injuries, including hemorrhage; perforation of tissues, vessels, and organs; heart attack; and even death.

Sometimes, it is too dangerous for surgeons to remove the filter, making a once retrievable IVC filter irretrievable. This is an injury in itself, attorneys warn.

Some of the lead IVC filter attorneys recommend patients who have retrievable filters get them checked by a doctor even if they’re not experiencing noticeable symptoms.

This can help reassure patients that the filter is in the correct position or even catch complications before they result in catastrophic injury. It can also serve as a reminder that the retrievable IVC filter needs to be — well — retrieved.

Even if there are no complications, people with retrievable IVC filters made by the medical device manufacturers C.R. Bard Inc., Cook Medical, or Cordis, may still be able to file a product in place claim.

Pa. Woman Files IVC Claim

Pittsburgh resident Nancy Kunsak filed a claim similar to PIP against C.R. Bard Inc., the maker of the Meridian® Filter System.

Kunsak was implanted with a Meridian® filter in February 2014 and it remains in place today, according to her complaint filed April 6, 2016.

She is suing Bard on three counts, including negligence, strict products liability, and negligent misrepresentation, and is calling for punitive damages.

The lawsuit accuses Bard of failing to conduct adequate clinical testing on its product and alleges the company knew or should have known the filter had a high rate of certain complications.

Kunsak is suing for damages, including physical pain and suffering, physical impairment and incapacity, mental anguish, medical expenses, and loss of earning capacity and wages, among others.

On top of Bard, Kunsak is suing two doctors who implanted the device and the hospital where the surgery took place. She accuses both doctors of not disclosing the full risks associated with the Meridian IVC filter and for not implementing a follow-up plan to remove the device when her risk for blood clots had subsided.

Her case, originally filed in state court in Pennsylvania, was removed to federal court and transferred into the IVC filter multidistrict litigation (MDL) in Arizona.

There are two MDLs pending against the IVC filter manufacturers C.R. Bard Inc. and Cook Medical. The Bard MDL was coordinated in the District of Arizona, while the Cook MDL was coordinated in the Southern District of Indiana. There were nearly 1,500 lawsuits pending in each MDL as of Feb. 15, 2017.

The case is Kunsak v. Kripoff, M.D. et al (2:17-cv-00555) and In Re: Bard IVC Filters Products Liability Litigation (MDL No. 2641) in the U.S. District Court for the District of Arizona.

IVC Filter Lawsuits

If you were implanted with an IVC filter made by C.R. Bard Inc., Cook Medical or Cordis, you may be able to file an IVC Lawsuit.

IVC filter lawsuits allege the manufacturers should have known about the risks associated with their devices but failed to warn consumers about those risks.

Contact the experienced attorneys at Hood National Law Group today for a free case evaluation. We can be reached 24 hours a day, 7 days a week at 1-800-214-1010 or simply fill out the form on the right-hand side of your screen to see if you qualify.

Photo Credit: Shutterstock.com/Kaesler Media

]]>
https://www.nationalinjuryhelp.com/defective-products/ivc-filter-lawsuits-without-complications/feed/ 0